Array BioPharma, a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, announced it has appointed Jason Haddock as chief financial officer. Mr. Haddock replaces David Horin, who had been acting as Array’s interim chief financial officer.

Mr. Haddock has more than 15 years of financial and operational experience in the biopharmaceutical industry. He held leadership positions of increasing responsibility at Bristol-Myers Squibb in a variety of accounting, planning, commercial, analytical and business development capacities over more than 13 years through 2015. Mr. Haddock most recently served as chief financial officer and chief operating officer of BERG Health, an oncology focused research, diagnostics and development company, where he oversaw the implementation of financial and operational processes, procedures and policies to transform and scale the company’s practices as it planned for growth and corporate evolution.

“We are pleased to welcome Jason to Array’s executive team during a pivotal time for our company,” said Ron Squarer, chief executive officer, Array. “He brings strong financial and operational expertise across many therapeutic areas and in commercial, medical and operational functions, and is well-versed on the nuances and challenges in the pharmaceutical landscape. We look forward to having Jason in this role as we continue to plan for commercialization of two wholly-owned drugs in the US.”